<?xml version="1.0" encoding="UTF-8"?><!DOCTYPE article  PUBLIC "-//NLM//DTD Journal Publishing DTD v3.0 20080202//EN" "http://dtd.nlm.nih.gov/publishing/3.0/journalpublishing3.dtd"><article xmlns:mml="http://www.w3.org/1998/Math/MathML" xmlns:xlink="http://www.w3.org/1999/xlink" dtd-version="3.0" xml:lang="en" article-type="research article"><front><journal-meta><journal-id journal-id-type="publisher-id">ACM</journal-id><journal-title-group><journal-title>Advances in Clinical Medicine</journal-title></journal-title-group><issn pub-type="epub">2161-8712</issn><publisher><publisher-name>Scientific Research Publishing</publisher-name></publisher></journal-meta><article-meta><article-id pub-id-type="doi">10.12677/ACM.2021.117442</article-id><article-id pub-id-type="publisher-id">ACM-43862</article-id><article-categories><subj-group subj-group-type="heading"><subject>ACM20210700000_77810788.pdf</subject></subj-group><subj-group subj-group-type="Discipline-v2"><subject>医药卫生</subject></subj-group></article-categories><title-group><article-title>
 
 
  能谱CT成像联合虚拟平扫鉴别肺癌病理类型的价值研究
  The Study of the Value of Spectral CT Imaging Combined with Virtual Non-Contrast in the Identification of Pathological Type of Lung Cancer
 
</article-title></title-group><contrib-group><contrib contrib-type="author" xlink:type="simple"><name name-style="western"><surname>史</surname><given-names>慧文</given-names></name><xref ref-type="aff" rid="aff2"><sup>2</sup></xref><xref ref-type="aff" rid="aff1"><sup>1</sup></xref></contrib><contrib contrib-type="author" xlink:type="simple"><name name-style="western"><surname>苗</surname><given-names>春萌</given-names></name><xref ref-type="aff" rid="aff2"><sup>2</sup></xref><xref ref-type="aff" rid="aff1"><sup>1</sup></xref></contrib><contrib contrib-type="author" xlink:type="simple"><name name-style="western"><surname>张</surname><given-names>金华</given-names></name><xref ref-type="aff" rid="aff2"><sup>2</sup></xref><xref ref-type="aff" rid="aff1"><sup>1</sup></xref></contrib><contrib contrib-type="author" xlink:type="simple"><name name-style="western"><surname>张</surname><given-names>在先</given-names></name><xref ref-type="aff" rid="aff2"><sup>2</sup></xref><xref ref-type="aff" rid="aff1"><sup>1</sup></xref></contrib><contrib contrib-type="author" xlink:type="simple"><name name-style="western"><surname>张</surname><given-names>传玉</given-names></name><xref ref-type="aff" rid="aff2"><sup>2</sup></xref><xref ref-type="aff" rid="aff1"><sup>1</sup></xref></contrib></contrib-group><aff id="aff2"><addr-line>青岛大学附属医院放射科，山东 青岛</addr-line></aff><aff id="aff1"><addr-line>null</addr-line></aff><pub-date pub-type="epub"><day>02</day><month>07</month><year>2021</year></pub-date><volume>11</volume><issue>07</issue><fpage>3047</fpage><lpage>3055</lpage><permissions><copyright-statement>&#169; Copyright  2014 by authors and Scientific Research Publishing Inc. </copyright-statement><copyright-year>2014</copyright-year><license><license-p>This work is licensed under the Creative Commons Attribution International License (CC BY). http://creativecommons.org/licenses/by/4.0/</license-p></license></permissions><abstract><p>
 
 
  目的：探讨能谱CT成像联合虚拟平扫鉴别肺癌病理类型的可行性。方法：前瞻性收集经病理证实的肺癌84例，所有病例术前均行能谱CT双期增强扫描。将病例分为腺癌组和鳞癌组，比较两组临床、影像特征及能谱参数的差异，能谱参数包括40~90 KeV单能量CT值、虚拟平扫CT
  <sub>70 KeV</sub>值、ΔCT值、标准化碘浓度(NIC)、标椎化水浓度(NWC)、40~90 keV曲线斜率(λ
  <sub>40~90 keV</sub>)，并对有统计学意义的参数用ROC曲线分析，评价其诊断效能。结果：鳞癌组中男性、有吸烟史患者的比例明显高于腺癌(P &lt; 0.05)。CT征象中，鳞癌多为中央型肺癌，腺癌多位于外周，腺癌胸膜牵拉及淋巴结肿大的发生率高于鳞癌，差异均有统计学意义(P &lt; 0.05)。两期CT
  <sub>40~70 KeV</sub>值、λ
  <sub>40~90 keV</sub>、NIC、ΔCT值和动脉期CT
  <sub>80 KeV</sub>值腺癌组高于鳞癌(P &lt; 0.05)，而虚拟平扫CT
  <sub>70 KeV</sub>值鳞癌组高于腺癌(P &lt; 0.05)，静脉期NWC有统计学意义(P &lt; 0.05)，但在两组中差别不大。ROC曲线显示能谱CT各参数诊断效能相比临床和影像更高，尤其是动脉期λ
  <sub>40~90 keV</sub> (AUC = 0.883)。结论：能谱CT成像联合虚拟平扫在鉴别肺癌病理类型方面的临床价值较大。
   Objective: To explore the possibility of spectral CT imaging combined with virtual non-contrast in the identification of pathological type of lung cancer. Methods: 84 patients with lung cancer confirmed by pathology were prospectively collected, all patients were examined by spectral CT dual-phase enhanced scanning before surgery. The patients were divided into adenocarcinoma group and squamous cell carcinoma group, the clinical date, CT findings and spectral parameters were compared between two groups. Spectral parameters included the CT values of 40~90 KeV, virtual non-contrast CT
  <sub>70 KeV</sub>, ΔCT value, normalized iodine concentration (NIC), normalized water concentration (NWC), the slope of 40~90 keV spectral curve (λ
  <sub>40~90 keV</sub>), ROC curve was used on the quantitative indexes with statistical difference to evaluate the diagnostic efficacy. Results: Compared with adenocarcinoma group, male, smoking patients were more common in squamous cell carcinoma group (P &lt; 0.05). In CT signs, most squamous cell carcinoma were central lung cancer, adenocarcinoma was more common seen in the peripheral part of the lung. In the adenocarcinoma group, the incidence of lymph node enlargement and pleural retraction were significantly higher than those in the squamous cell carcinoma group (P &lt; 0.05). The CT values of 40~70 KeV, λ
  <sub>40~90 keV</sub>, NIC、the value of ΔCT in two phases and the CT values of 80 KeV in the arterial phase in the adenocarcinoma group were significantly higher than those in the squamous cell carcinoma group (P &lt; 0.05), virtual non-contrast CT
  <sub>70 KeV</sub> of the squamous cell carcinoma group was higher than that of the adenocarcinoma group (P &lt; 0.05), there was little difference in NWC in venous phase between two groups which had statistical difference (P &lt; 0.05). ROC curve showed that spectral parameters had higher diagnostic efficiency than clinical and CT parameters, especially λ40~90 keV in arterial phase (AUC = 0.883). Conclusion: Spectral CT imaging combined with virtual non-contrast has a certain clinical value in the identification of pathological type of lung cancer.
 
</p></abstract><kwd-group><kwd>肺癌，病理分型，能谱CT，虚拟平扫, Lung Cancer</kwd><kwd> Pathological Typing</kwd><kwd> Spectrum CT</kwd><kwd> Virtual Non-Contrast</kwd></kwd-group></article-meta></front><body><sec id="s1"><title>摘要</title><p>目的：探讨能谱CT成像联合虚拟平扫鉴别肺癌病理类型的可行性。方法：前瞻性收集经病理证实的肺癌84例，所有病例术前均行能谱CT双期增强扫描。将病例分为腺癌组和鳞癌组，比较两组临床、影像特征及能谱参数的差异，能谱参数包括40~90 KeV单能量CT值、虚拟平扫CT<sub>70 KeV</sub>值、ΔCT值、标准化碘浓度(NIC)、标椎化水浓度(NWC)、40~90 keV曲线斜率(λ<sub>40~90 keV</sub>)，并对有统计学意义的参数用ROC曲线分析，评价其诊断效能。结果：鳞癌组中男性、有吸烟史患者的比例明显高于腺癌(P &lt; 0.05)。CT征象中，鳞癌多为中央型肺癌，腺癌多位于外周，腺癌胸膜牵拉及淋巴结肿大的发生率高于鳞癌，差异均有统计学意义(P &lt; 0.05)。两期CT<sub>40~70 KeV</sub>值、λ<sub>40~90 keV</sub>、NIC、ΔCT值和动脉期CT<sub>80 KeV</sub>值腺癌组高于鳞癌(P &lt; 0.05)，而虚拟平扫CT<sub>70 KeV</sub>值鳞癌组高于腺癌(P &lt; 0.05)，静脉期NWC有统计学意义(P &lt; 0.05)，但在两组中差别不大。ROC曲线显示能谱CT各参数诊断效能相比临床和影像更高，尤其是动脉期λ<sub>40~90 keV</sub> (AUC = 0.883)。结论：能谱CT成像联合虚拟平扫在鉴别肺癌病理类型方面的临床价值较大。</p></sec><sec id="s2"><title>关键词</title><p>肺癌，病理分型，能谱CT，虚拟平扫</p></sec><sec id="s3"><title>The Study of the Value of Spectral CT Imaging Combined with Virtual Non-Contrast in the Identification of Pathological Type of Lung Cancer<sup> </sup></title><p>Huiwen Shi, Chunmeng Miao, Jinhua Zhang, Zaixian Zhang, Chuanyu Zhang<sup>*</sup></p><p>Department of Radiology, Affiliated Hospital of Qingdao University, Qingdao Shandong</p><p><img src="//html.hanspub.org/file/23-1572353x5_hanspub.png?20210715080220530" /></p><p>Received: Jun. 9<sup>th</sup>, 2021; accepted: Jul. 1<sup>st</sup>, 2021; published: Jul. 14<sup>th</sup>, 2021</p><p><img src="//html.hanspub.org/file/23-1572353x6_hanspub.png?20210715080220530" /></p></sec><sec id="s4"><title>ABSTRACT</title><p>Objective: To explore the possibility of spectral CT imaging combined with virtual non-contrast in the identification of pathological type of lung cancer. Methods: 84 patients with lung cancer confirmed by pathology were prospectively collected, all patients were examined by spectral CT dual-phase enhanced scanning before surgery. The patients were divided into adenocarcinoma group and squamous cell carcinoma group, the clinical date, CT findings and spectral parameters were compared between two groups. Spectral parameters included the CT values of 40~90 KeV, virtual non-contrast CT<sub>70 KeV</sub>, ΔCT value, normalized iodine concentration (NIC), normalized water concentration (NWC), the slope of 40~90 keV spectral curve (λ<sub>40~90 keV</sub>), ROC curve was used on the quantitative indexes with statistical difference to evaluate the diagnostic efficacy. Results: Compared with adenocarcinoma group, male, smoking patients were more common in squamous cell carcinoma group (P &lt; 0.05). In CT signs, most squamous cell carcinoma were central lung cancer, adenocarcinoma was more common seen in the peripheral part of the lung. In the adenocarcinoma group, the incidence of lymph node enlargement and pleural retraction were significantly higher than those in the squamous cell carcinoma group (P &lt; 0.05). The CT values of 40~70 KeV, λ<sub>40~90 keV</sub>, NIC、the value of ΔCT in two phases and the CT values of 80 KeV in the arterial phase in the adenocarcinoma group were significantly higher than those in the squamous cell carcinoma group (P &lt; 0.05), virtual non-contrast CT<sub>70 KeV</sub> of the squamous cell carcinoma group was higher than that of the adenocarcinoma group (P &lt; 0.05), there was little difference in NWC in venous phase between two groups which had statistical difference (P &lt; 0.05). ROC curve showed that spectral parameters had higher diagnostic efficiency than clinical and CT parameters, especially λ<sub>40~90 keV</sub> in arterial phase (AUC = 0.883). Conclusion: Spectral CT imaging combined with virtual non-contrast has a certain clinical value in the identification of pathological type of lung cancer.</p><p>Keywords:Lung Cancer, Pathological Typing, Spectrum CT, Virtual Non-Contrast</p><disp-formula id="hanspub.43862-formula15"><graphic xlink:href="//html.hanspub.org/file/23-1572353x7_hanspub.png?20210715080220530"  xlink:type="simple"/></disp-formula><p>Copyright &#169; 2021 by author(s) and Hans Publishers Inc.</p><p>This work is licensed under the Creative Commons Attribution International License (CC BY 4.0).</p><p>http://creativecommons.org/licenses/by/4.0/</p><p><img src="//html.hanspub.org/file/23-1572353x8_hanspub.png?20210715080220530" /> <img src="//html.hanspub.org/file/23-1572353x9_hanspub.png?20210715080220530" /></p></sec><sec id="s5"><title>1. 引言</title><p>截至目前为止，肺癌仍然是世界死亡率第一的恶性肿瘤。非小细胞肺癌(NSCLC)约占肺癌的85%，而鳞状细胞癌(SCC)和肺腺癌(LAC)是非小细胞肺癌最主要的两个组织亚型 [<xref ref-type="bibr" rid="hanspub.43862-ref1">1</xref>] [<xref ref-type="bibr" rid="hanspub.43862-ref2">2</xref>]。目前，活检仍是肿瘤诊断的金标准，但其作为一种有创检查也有很多的局限性，例如取材有限、有禁忌症等。能谱CT成像作为一种新的检查手段，其特征性的多参数成像不仅可以从传统的形态学方面还能从功能学上评价肿瘤的特性，在肿瘤的诊断、病理分型、淋巴结转移评价等方面都有较大的应用价值 [<xref ref-type="bibr" rid="hanspub.43862-ref3">3</xref>]。本研究前瞻性收集术前进行能谱CT增强检查的肺癌患者，旨在探讨能谱CT多参数定量分析鉴别肺癌病理类型的价值。</p></sec><sec id="s6"><title>2. 资料与方法</title><sec id="s6_1"><title>2.1. 一般资料</title><p>收集2020.12~2021.4在本院接受胸部能谱CT双期增强扫描检查且经病理证实的肺癌患者84例，男性54例，女性30例，年龄34~81岁，平均(64.10 &#177; 8.56)岁，其中包括肺腺癌50例，肺鳞癌34例。</p></sec><sec id="s6_2"><title>2.2. 选取标准</title><p>纳入标准：(1) 检查前没有进行过任何治疗；(2) 经病理证实为NSCLC；(3) 纵隔窗能观察到实性成分；(4) 病灶无影响测量的空洞或肺不张。排除标准：(1) 同时合并其他肿瘤患者；(2) 纳入研究前进行了抗肿瘤相关治疗。</p></sec><sec id="s6_3"><title>2.3. 检查方法</title><p>采用GE Revolution能谱CT机，所有患者均在能谱扫描模式(GSI)下行胸部动静脉双期增强扫描。扫描范围自肺尖至肺底膈面，GSI扫描参数选择如下：管电压80 kVp、140 kVp瞬时切换(0.5 ms)，自动管电流技术(200~500 mAs)，测器宽度80 mm，旋转速度0.5 s/r，螺距0.992:1，扫描野50 cm &#215; 50 cm，层厚和层间距5 mm。对比剂选用碘海醇(350 mgI/ml)，采用高压注射器经肘窝处静脉注射，注射速3.0 ml/s，注射量70~80 ml，根据体重适当调节，于注射对比剂后25 s、60 s分别行动脉期、静脉期扫描。原始数据在扫描机上自动重建为层厚1.25 mm的图像及动静脉期70 KeV虚拟平扫图像(virtual non-contrast, VNC)。</p></sec><sec id="s6_4"><title>2.4. 图像分析</title><p>图像采集结束传至GE AW4.6工作站，应用GSI Viewer软件进行分析处理。由两名具有5年以上经验的医师分别观察图像并分析、评价常规CT征象，包括肿瘤位置(周围/中央)、钙化、分叶征、毛刺征、空泡征、支气管截断、血管集束、胸膜牵拉和淋巴结肿大。ROI选取病灶横断面最大层面及其邻近上、下层面，取三者平均值，确保增强两期ROI大小、形态及位置尽量一致，密度均匀时ROI面积不小于病灶横断面的2/3，密度不均匀时，感兴趣区尽量包括所有实性成分。测量后自动得到病灶40~90 KeV单能量CT值、碘浓度、水浓度。用相同的方法测量同层胸主动脉或锁骨下动脉碘浓度、水浓度及虚拟平扫CT<sub>70 KeV</sub>值。计算40~90 keV曲线斜率(λ<sub>40~90 keV</sub>)、标准化碘浓度(normalized iodine concentration, NIC)、标椎化水浓度(normalized water concentration, NWC)、ΔCT值。NIC = 病灶碘浓度/主动脉碘浓度；NWC = 病灶水浓度/主动脉水浓度；λ<sub>40~90 keV</sub> = (CT<sub>40 KeV</sub>值 − CT<sub>90 KeV</sub>值)/(90 − 40)；ΔCT值 = CT<sub>70 KeV</sub>值 − 虚拟平扫CT<sub>70 KeV</sub>值。</p></sec><sec id="s6_5"><title>2.5. 统计学分析</title><p>本数据采用SPSS 26.0软件进行统计学分析，计量资料若符合正态分布，采用独立样本t检验，以均值加减标准差(x &#177; s)表示，若不符合正态分布，采用Mann-Whitney U检验，以中位数(四分位数间距)表示。分类资料采用c<sup>2</sup>检验，以百分数(%)表示。以P &lt; 0.05为有统计学意义。采用受试者工作曲线(receiver operator characteristic curve, ROC curve)分析各参数的诊断效能，曲线下面积(area under the curve, AUC)越大诊断效能越高。</p></sec></sec><sec id="s7"><title>3. 结果</title><sec id="s7_1"><title>3.1. 临床、影像特征</title><p>鳞癌中男性及有吸烟史者明显高于腺癌，差异有统计学意义(P &lt; 0.05)，年龄在两组中无统计学意义(P &gt; 0.05) (表1)。CT征象中，鳞癌组中央型居多，腺癌多位于外周，腺癌胸膜牵拉及淋巴结肿大发生率较鳞癌高，差异有统计学意义(P &lt; 0.05)，其余征象无统计学意义(P &gt; 0.05) (表2)。</p><table-wrap id="table1" ><label><xref ref-type="table" rid="table1">Table 1</xref></label><caption><title> The comparison of clinical data of adenocarcinoma and squamous cell carcinom</title></caption><table><tbody><thead><tr><th align="center" valign="middle" >组别</th><th align="center" valign="middle" >例数</th><th align="center" valign="middle" >男/女(例)</th><th align="center" valign="middle" >年龄(岁)</th><th align="center" valign="middle" >吸烟史(例，有/无)</th></tr></thead><tr><td align="center" valign="middle" >腺癌</td><td align="center" valign="middle" >50</td><td align="center" valign="middle" >22/28</td><td align="center" valign="middle" >65.5 (14)</td><td align="center" valign="middle" >16/34</td></tr><tr><td align="center" valign="middle" >鳞癌</td><td align="center" valign="middle" >34</td><td align="center" valign="middle" >32/2</td><td align="center" valign="middle" >66.6 (13)</td><td align="center" valign="middle" >29/5</td></tr><tr><td align="center" valign="middle" >c<sup>2</sup>/Z</td><td align="center" valign="middle" ></td><td align="center" valign="middle" >22.141</td><td align="center" valign="middle" >0.379</td><td align="center" valign="middle" >23.111</td></tr><tr><td align="center" valign="middle" >P值</td><td align="center" valign="middle" ></td><td align="center" valign="middle" >0.000</td><td align="center" valign="middle" >0.705</td><td align="center" valign="middle" >0.000</td></tr></tbody></table></table-wrap><p>表1. 肺腺癌和肺鳞癌患者临床资料比较</p><table-wrap id="table2" ><label><xref ref-type="table" rid="table2">Table 2</xref></label><caption><title> The comparison of CT signs of adenocarcinoma and squamous cell carcinom</title></caption><table><tbody><thead><tr><th align="center" valign="middle" >组别</th><th align="center" valign="middle" >例数</th><th align="center" valign="middle" >位置 (中央/周围)</th><th align="center" valign="middle" >空泡征 (有/无)</th><th align="center" valign="middle" >钙化 (有/无)</th><th align="center" valign="middle" >分叶 (有/无)</th><th align="center" valign="middle" >毛刺 (有/无)</th><th align="center" valign="middle" >支气管截断 (有/无)</th><th align="center" valign="middle" >血管集束 (有/无)</th><th align="center" valign="middle" >胸膜牵拉 (有/无)</th><th align="center" valign="middle" >淋巴结肿大 (有/无)</th></tr></thead><tr><td align="center" valign="middle" >腺癌</td><td align="center" valign="middle" >50</td><td align="center" valign="middle" >19/31</td><td align="center" valign="middle" >14/36</td><td align="center" valign="middle" >4/46</td><td align="center" valign="middle" >41/9</td><td align="center" valign="middle" >31/19</td><td align="center" valign="middle" >25/25</td><td align="center" valign="middle" >11/39</td><td align="center" valign="middle" >32/18</td><td align="center" valign="middle" >24/26</td></tr><tr><td align="center" valign="middle" >鳞癌</td><td align="center" valign="middle" >34</td><td align="center" valign="middle" >25/9</td><td align="center" valign="middle" >6/28</td><td align="center" valign="middle" >2/32</td><td align="center" valign="middle" >27/7</td><td align="center" valign="middle" >16/18</td><td align="center" valign="middle" >20/14</td><td align="center" valign="middle" >4/30</td><td align="center" valign="middle" >12/22</td><td align="center" valign="middle" >9/25</td></tr><tr><td align="center" valign="middle" >c<sup>2</sup></td><td align="center" valign="middle" ></td><td align="center" valign="middle" >10.242</td><td align="center" valign="middle" >1.196</td><td align="center" valign="middle" >0.137</td><td align="center" valign="middle" >0.088</td><td align="center" valign="middle" >1.833</td><td align="center" valign="middle" >0.633</td><td align="center" valign="middle" >1.445</td><td align="center" valign="middle" >6.686</td><td align="center" valign="middle" >3.933</td></tr><tr><td align="center" valign="middle" >P值</td><td align="center" valign="middle" ></td><td align="center" valign="middle" >0.001</td><td align="center" valign="middle" >0.274</td><td align="center" valign="middle" >0.711</td><td align="center" valign="middle" >0.767</td><td align="center" valign="middle" >0.176</td><td align="center" valign="middle" >0.426</td><td align="center" valign="middle" >0.229</td><td align="center" valign="middle" >0.010</td><td align="center" valign="middle" >0.047</td></tr></tbody></table></table-wrap><p>表2. 肺腺癌和肺鳞癌CT征象比较</p></sec><sec id="s7_2"><title>3.2. 能谱CT参数</title><p>两期CT<sub>40~70 KeV</sub>值、λ<sub>40~90 keV</sub>、NIC、虚拟平扫CT<sub>70 KeV</sub>值及ΔCT值均有统计学意义(P &lt; 0.05)，CT<sub>80 KeV</sub>值、NWC分别在动脉期、静脉期有统计学意义(P &lt; 0.05)，其余参数无统计学意义(P &gt; 0.05) (表3、表4) (图1、图2)。</p><table-wrap id="table3" ><label><xref ref-type="table" rid="table3">Table 3</xref></label><caption><title> The comparison of spectral CT parameters in arterial phase of adenocarcinoma and squamous cell carcinom</title></caption><table><tbody><thead><tr><th align="center" valign="middle" >参数</th><th align="center" valign="middle" >腺癌(n = 50)</th><th align="center" valign="middle" >鳞癌(n = 34)</th><th align="center" valign="middle" >t/Z值</th><th align="center" valign="middle" >P值</th></tr></thead><tr><td align="center" valign="middle" >40 KeV CT值</td><td align="center" valign="middle" >183.81 &#177; 51.91</td><td align="center" valign="middle" >115.57 &#177; 32.67</td><td align="center" valign="middle" >7.390</td><td align="center" valign="middle" >0.000</td></tr><tr><td align="center" valign="middle" >50 KeV CT值</td><td align="center" valign="middle" >124.42 &#177; 31.64</td><td align="center" valign="middle" >83.18 &#177; 22.07</td><td align="center" valign="middle" >7.036</td><td align="center" valign="middle" >0.000</td></tr><tr><td align="center" valign="middle" >60 KeV CT值</td><td align="center" valign="middle" >87.89 &#177; 22.07</td><td align="center" valign="middle" >63.17 &#177; 16.36</td><td align="center" valign="middle" >5.735</td><td align="center" valign="middle" >0.000</td></tr><tr><td align="center" valign="middle" >70 KeV CT值</td><td align="center" valign="middle" >65.17 &#177; 17.13</td><td align="center" valign="middle" >50.78 &#177; 13.46</td><td align="center" valign="middle" >4.109</td><td align="center" valign="middle" >0.000</td></tr><tr><td align="center" valign="middle" >80 KeV CT值</td><td align="center" valign="middle" >49.72 (17.75)</td><td align="center" valign="middle" >43.89 (13.74)</td><td align="center" valign="middle" >2.834</td><td align="center" valign="middle" >0.005</td></tr><tr><td align="center" valign="middle" >90 KeV CT值</td><td align="center" valign="middle" >44.42 (15.34)</td><td align="center" valign="middle" >38.21 (11.03)</td><td align="center" valign="middle" >1.622</td><td align="center" valign="middle" >0.105</td></tr><tr><td align="center" valign="middle" >标准化碘浓度(NIC)</td><td align="center" valign="middle" >0.19 (0.09)</td><td align="center" valign="middle" >0.11 (0.05)</td><td align="center" valign="middle" >5.140</td><td align="center" valign="middle" >0.000</td></tr><tr><td align="center" valign="middle" >标准化水浓度(NWC)</td><td align="center" valign="middle" >0.99 (0.02)</td><td align="center" valign="middle" >0.99 (0.02)</td><td align="center" valign="middle" >0.857</td><td align="center" valign="middle" >0.392</td></tr><tr><td align="center" valign="middle" >能谱曲线斜率(λ<sub>40~90 keV</sub>)</td><td align="center" valign="middle" >2.86 &#177; 1.07</td><td align="center" valign="middle" >1.56 &#177; 0.56</td><td align="center" valign="middle" >7.253</td><td align="center" valign="middle" >0.000</td></tr><tr><td align="center" valign="middle" >虚拟平扫CT值</td><td align="center" valign="middle" >31.00 (12.29)</td><td align="center" valign="middle" >34.46 (8.89)</td><td align="center" valign="middle" >0.857</td><td align="center" valign="middle" >0.011</td></tr><tr><td align="center" valign="middle" >ΔCT<sub>70</sub><sub> </sub><sub>KeV</sub>值</td><td align="center" valign="middle" >36.78 &#177; 17.81</td><td align="center" valign="middle" >17.56 &#177; 9.94</td><td align="center" valign="middle" >5.710</td><td align="center" valign="middle" >0.000</td></tr></tbody></table></table-wrap><p>表3. 动脉期肺腺癌和肺鳞癌能谱CT参数比较</p><table-wrap id="table4" ><label><xref ref-type="table" rid="table4">Table 4</xref></label><caption><title> The comparison of spectral CT parameters in venous phase of adenocarcinoma and squamous cell carcinom</title></caption><table><tbody><thead><tr><th align="center" valign="middle" >参数</th><th align="center" valign="middle" >腺癌(n = 50)</th><th align="center" valign="middle" >鳞癌(n = 34)</th><th align="center" valign="middle" >t/Z值</th><th align="center" valign="middle" >P值</th></tr></thead><tr><td align="center" valign="middle" >40 KeV CT值</td><td align="center" valign="middle" >206.49 &#177; 40.37</td><td align="center" valign="middle" >151.09 &#177; 35.12</td><td align="center" valign="middle" >6.500</td><td align="center" valign="middle" >0.000</td></tr><tr><td align="center" valign="middle" >50 KeV CT值</td><td align="center" valign="middle" >141.75 &#177; 28.21</td><td align="center" valign="middle" >107.34 &#177; 24.52</td><td align="center" valign="middle" >5.780</td><td align="center" valign="middle" >0.000</td></tr><tr><td align="center" valign="middle" >60 KeV CT值</td><td align="center" valign="middle" >100.61 &#177; 20.02</td><td align="center" valign="middle" >80.39 &#177; 18.67</td><td align="center" valign="middle" >4.667</td><td align="center" valign="middle" >0.000</td></tr><tr><td align="center" valign="middle" >70 KeV CT值</td><td align="center" valign="middle" >75.04 &#177; 16.57</td><td align="center" valign="middle" >63.62 &#177; 15.55</td><td align="center" valign="middle" >3.176</td><td align="center" valign="middle" >0.002</td></tr><tr><td align="center" valign="middle" >80 KeV CT值</td><td align="center" valign="middle" >58.70 &#177; 15.4</td><td align="center" valign="middle" >52.91 &#177; 13.96</td><td align="center" valign="middle" >1.747</td><td align="center" valign="middle" >0.084</td></tr><tr><td align="center" valign="middle" >90 KeV CT值</td><td align="center" valign="middle" >48.28 (17.28)</td><td align="center" valign="middle" >45.60 (14.90)</td><td align="center" valign="middle" >0.893</td><td align="center" valign="middle" >0.372</td></tr><tr><td align="center" valign="middle" >标准化碘浓度(NIC)</td><td align="center" valign="middle" >0.47 (0.19)</td><td align="center" valign="middle" >0.35 (0.13)</td><td align="center" valign="middle" >4.311</td><td align="center" valign="middle" >0.000</td></tr><tr><td align="center" valign="middle" >标准化水浓度(NWC)</td><td align="center" valign="middle" >0.99 (0.02)</td><td align="center" valign="middle" >0.99 (0.01)</td><td align="center" valign="middle" >2.033</td><td align="center" valign="middle" >0.045</td></tr><tr><td align="center" valign="middle" >能谱曲线斜率(λ<sub>40~90 keV</sub>)</td><td align="center" valign="middle" >3.14 &#177; 0.79</td><td align="center" valign="middle" >2.11 &#177; 0.56</td><td align="center" valign="middle" >6.555</td><td align="center" valign="middle" >0.000</td></tr><tr><td align="center" valign="middle" >虚拟平扫CT值</td><td align="center" valign="middle" >30.13 (14.89)</td><td align="center" valign="middle" >37.53 (8.96)</td><td align="center" valign="middle" >2.971</td><td align="center" valign="middle" >0.003</td></tr><tr><td align="center" valign="middle" >ΔCT<sub>70</sub><sub> </sub><sub>KeV</sub>值</td><td align="center" valign="middle" >45.85 &#177; 16.57</td><td align="center" valign="middle" >28.70 &#177; 11.46</td><td align="center" valign="middle" >5.238</td><td align="center" valign="middle" >0.000</td></tr></tbody></table></table-wrap><p>表4. 静脉期肺腺癌和肺鳞癌能谱CT参数比较</p><p>图1. 女，71，无吸烟史。右肺下叶腺癌。(a)~(f)分别为动脉期肺窗、动脉期40 KeV纵隔窗、70 KeV虚拟平扫图、碘基图、水基图、能谱曲线图，其中虚拟平扫CT值为53.90 Hu，碘浓度为18.99 mg/cm<sup>3</sup>，水含量为1042.18 mg/cm<sup>3</sup></p><p>图2. 男，66，有吸烟史。左肺上叶鳞癌。(a)~(f)分别为动脉期肺窗、动脉期40 KeV纵隔窗、70 KeV虚拟平扫图、碘基图、水基图、能谱曲线图，其中虚拟平扫CT值为31.38 Hu，碘浓度为14.07 mg/cm<sup>3</sup>，水含量为1019.14 mg/cm<sup>3</sup></p></sec><sec id="s7_3"><title>3.3. ROC曲线分析</title><p>能谱各参数曲线下面积相对于临床和CT征象更大，动脉期λ<sub>40~90 keV</sub>具有较高的灵敏度和特异度，分别为78.0%和85.3%，AUC为0.883，在所有参数中诊断效能最好(表5) (图3)。</p><p>图3. 肺腺癌和肺鳞癌各组最具诊断效能参数的ROC曲线</p><table-wrap id="table5" ><label><xref ref-type="table" rid="table5">Table 5</xref></label><caption><title> The comparison of ROC curve of the best diagnostic efficiency parameters of adenocarcinoma and quamous cell carcinom</title></caption><table><tbody><thead><tr><th align="center" valign="middle" >参数</th><th align="center" valign="middle" >约登指数</th><th align="center" valign="middle" >临界值</th><th align="center" valign="middle" >灵敏度(%)</th><th align="center" valign="middle" >特异度(%)</th><th align="center" valign="middle" >曲线下面积</th></tr></thead><tr><td align="center" valign="middle" >吸烟史</td><td align="center" valign="middle" >0.533</td><td align="center" valign="middle" >0.50</td><td align="center" valign="middle" >85.3</td><td align="center" valign="middle" >68.0</td><td align="center" valign="middle" >0.766</td></tr><tr><td align="center" valign="middle" >位置</td><td align="center" valign="middle" >0.355</td><td align="center" valign="middle" >0.50</td><td align="center" valign="middle" >62.0</td><td align="center" valign="middle" >73.5</td><td align="center" valign="middle" >0.678</td></tr><tr><td align="center" valign="middle" >动脉期λ<sub>40</sub><sub>~</sub><sub>90</sub><sub> </sub><sub>keV</sub></td><td align="center" valign="middle" >0.633</td><td align="center" valign="middle" >2.12</td><td align="center" valign="middle" >78.0</td><td align="center" valign="middle" >85.3</td><td align="center" valign="middle" >0.883</td></tr><tr><td align="center" valign="middle" >静脉期λ<sub>40</sub><sub>~</sub><sub>90</sub><sub> </sub><sub>keV</sub></td><td align="center" valign="middle" >0.630</td><td align="center" valign="middle" >2.58</td><td align="center" valign="middle" >78.0</td><td align="center" valign="middle" >85.0</td><td align="center" valign="middle" >0.862</td></tr></tbody></table></table-wrap><p>表5. 肺腺癌和肺鳞癌各组最具诊断效能参数的ROC曲线比较</p></sec></sec><sec id="s8"><title>4. 讨论</title><p>肺癌的发病率和死亡率在我国一直处于首位 [<xref ref-type="bibr" rid="hanspub.43862-ref4">4</xref>]。虽然人们肺癌筛查意识逐渐提高，但由于其早期症状不明显，仍然有很多患者确诊时已处于晚期。有文献 [<xref ref-type="bibr" rid="hanspub.43862-ref5">5</xref>] 报道，不可切除局部晚期和转移性NSCLC约占肺癌的50%~60%，晚期肺癌的治疗方式多样，如化疗、放疗、靶向治疗、免疫治疗等，肺癌病理分型对于治疗方法选择和预后评估有重要意义。以往传统的CT图像主要通过形态学及增强后强化程度对病灶性质进行初步判断，对于病理分型的评估价值有限。能谱CT通过其特有的80 KeV、140 KeV两种能量瞬时切换技术，利用一次扫描后获得的40~140 KeV单能量图像、有效原子序数图、物质分离图像、能谱曲线等进行多参数定量分析，使CT诊断不再仅局限于形态学方面 [<xref ref-type="bibr" rid="hanspub.43862-ref6">6</xref>]。</p><p>以往已有研究 [<xref ref-type="bibr" rid="hanspub.43862-ref3">3</xref>] [<xref ref-type="bibr" rid="hanspub.43862-ref7">7</xref>] - [<xref ref-type="bibr" rid="hanspub.43862-ref12">12</xref>] 显示，能谱CT扫描在肺癌病理分型中有重要的应用价值，本研究通过观察临床、影像特征及能谱参数，并用能谱CT的虚拟平扫图像代替常规平扫，旨在进一步评价能谱CT在肺癌病理分型中的价值。</p><sec id="s8_1"><title>4.1. 临床、影像特征分析</title><p>张仁锋等 [<xref ref-type="bibr" rid="hanspub.43862-ref13">13</xref>] 对6058例肺癌研究发现，鳞癌中男性和吸烟者占比明显高于腺癌，本研究结果与其相符；CT征象中，肿瘤的位置、胸膜牵拉及淋巴结肿大与病理类型有相关性，中央型肺癌多为鳞癌而周围型肺癌多为腺癌，腺癌胸膜牵拉发生率高于鳞癌，推测可能与腺癌多位于外周有关；有研究 [<xref ref-type="bibr" rid="hanspub.43862-ref14">14</xref>] 证实，腺癌更容易发生淋巴结转移，这与本研究结果相符。</p></sec><sec id="s8_2"><title>4.2. 能谱参数分析</title><p>能谱CT通过双能量瞬时切换技术扫描完成后可以获得40~140 KeV单能量图像，相比于混合能量图像，单能量图像有更好的图像质量、信噪比和对比噪声比 [<xref ref-type="bibr" rid="hanspub.43862-ref6">6</xref>]。能谱CT的虚拟平扫图像(VNC)本质是物质分离图像，即将增强图像中的碘分离出去而获得的抑碘图，研究 [<xref ref-type="bibr" rid="hanspub.43862-ref15">15</xref>] [<xref ref-type="bibr" rid="hanspub.43862-ref16">16</xref>] 证实VNC可以代替常规平扫满足诊断需要，同时因为避免了一次扫描可以明显减少患者辐射剂量。本研究结果显示，动静脉期CT<sub>40~70 KeV</sub>值、虚拟平扫CT<sub>70 KeV</sub>值、ΔCT值及动脉期CT<sub>80 KeV</sub>值在两组间有统计学意义，除了虚拟平扫CT<sub>70 KeV</sub>为鳞癌高于腺癌，其余参数均为腺癌高于鳞癌。考虑上述结果的出现主要与肿瘤的组织结构差异及强化程度有关，虚拟平扫CT<sub>70 KeV</sub>值受组织结构影响较大，而增强扫描中各参数主要受强化程度的影响。肺腺癌以伏壁生长方式为主，组织结构疏松，血管和间质丰富，而肺鳞癌呈堆积式生长，结构致密，间质间血管较少，故平扫时鳞癌的CT值通常高于腺癌，而增强后腺癌强化程度高于鳞癌，与之对应，增强后各参数均高于鳞癌。这与前者研究 [<xref ref-type="bibr" rid="hanspub.43862-ref7">7</xref>] 相符。</p><p>物质分离是将一种物质的衰减系数转化为高低两种不同衰减系数基物质的方法，最常用的基物质是碘和水，因为这两种物质包含了从软组织到碘对比剂及一些医学常见物质的范围 [<xref ref-type="bibr" rid="hanspub.43862-ref6">6</xref>]。由于病灶内碘浓度的差异容易受个体差异、对比剂流速及总量等影响，因此本研究用标准化碘浓度(NIC)、标准化水浓度(NWC)来排除这种影响。标准化碘浓度反映了组织内碘含量，也间接反映了组织血管内碘含量。本研究中动静脉期腺癌NIC均大于鳞癌，且具有统计学意义，可能与腺癌微血管密度大、血供更丰富有关 [<xref ref-type="bibr" rid="hanspub.43862-ref7">7</xref>]，与以往文献 [<xref ref-type="bibr" rid="hanspub.43862-ref11">11</xref>] [<xref ref-type="bibr" rid="hanspub.43862-ref12">12</xref>] 相符。鳞癌呈堆积式生长，其组织致密，单位体积内肿瘤细胞较腺癌更多、含水量更大，多项研究 [<xref ref-type="bibr" rid="hanspub.43862-ref3">3</xref>] [<xref ref-type="bibr" rid="hanspub.43862-ref7">7</xref>] [<xref ref-type="bibr" rid="hanspub.43862-ref12">12</xref>] 显示肺鳞癌水浓度高于腺癌，而本研究两种病理类型之间NWC差别不大，可能与样本选择偏倚有关。</p><p>能谱曲线反映了不同能量水平下物质CT值的变化，同一物质在不同能量下对X线吸收系数不同，不同物质在同一能量水平下吸收系数也不同 [<xref ref-type="bibr" rid="hanspub.43862-ref12">12</xref>]。由于X线能量越低，吸收系数越大，衰减量越多，所以能谱曲线总体呈下降趋势，有研究 [<xref ref-type="bibr" rid="hanspub.43862-ref12">12</xref>] 显示CT值在40~90 KeV水平变化最大，故本研究选择λ<sub>40~90keV</sub>作为观察指标。能谱曲线的大小用斜率表示，主要与组织的成分和结构有关，也受组织对碘对比剂吸收情况的影响。本研究中动静脉期λ<sub>40~90 keV</sub>均有统计学差异，且腺癌组高于鳞癌组，可能与腺癌血管丰富有关，与以往研究 [<xref ref-type="bibr" rid="hanspub.43862-ref3">3</xref>] [<xref ref-type="bibr" rid="hanspub.43862-ref11">11</xref>] [<xref ref-type="bibr" rid="hanspub.43862-ref12">12</xref>] 相符。</p><p>将有统计学意义的参数进行ROC曲线分析发现，能谱各参数相对于临床和CT征象曲线下面积更大，动脉期λ<sub>40~90 keV</sub>在所有参数中的诊断效能最高，灵敏度和特异度分别为78.0%和85.3%，AUC最大为0.883。</p><p>综上所述，能谱CT成像联合虚拟平扫在鉴别不同病理类型肺癌中有一定的应用价值，且相比于常规CT，能谱CT成像的诊断价值更大。</p></sec></sec><sec id="s9"><title>利益冲突</title><p>所有作者均声明不存在利益冲突。</p></sec><sec id="s10"><title>文章引用</title><p>史慧文,苗春萌,张金华,张在先,张传玉. 能谱CT成像联合虚拟平扫鉴别肺癌病理类型的价值研究The Study of the Value of Spectral CT Imaging Combined with Virtual Non-Contrast in the Identification of Pathological Type of Lung Cancer[J]. 临床医学进展, 2021, 11(07): 3047-3055. https://doi.org/10.12677/ACM.2021.117442</p></sec><sec id="s11"><title>参考文献</title></sec></body><back><ref-list><title>References</title><ref id="hanspub.43862-ref1"><label>1</label><mixed-citation publication-type="other" xlink:type="simple">Siegel, R.L., et al. (2021) Cancer Statistics, 2021. CA: A Cancer Journal for Clinicians, 71, 7-33.  
&lt;br&gt;https://doi.org/10.3322/caac.21654</mixed-citation></ref><ref id="hanspub.43862-ref2"><label>2</label><mixed-citation publication-type="other" xlink:type="simple">Hyuna, S., Jacques, F., et al. (2021) Global Cancer Statistics 2020: GLOBOCAN Estimates of Incidence and Mortality Worldwide for 36 Cancers in 185 Countries. CA: A Cancer Journal for Clinicians, 71, 209-249.  
&lt;br&gt;https://doi.org/10.3322/caac.21660</mixed-citation></ref><ref id="hanspub.43862-ref3"><label>3</label><mixed-citation publication-type="other" xlink:type="simple">史志勇. 能谱CT定量分析在非小细胞肺癌术前诊断中的临床价值[J]. 中国CT和MRI杂志, 2020, 18(9): 76-78+177.</mixed-citation></ref><ref id="hanspub.43862-ref4"><label>4</label><mixed-citation publication-type="other" xlink:type="simple">Chen, W., et al. (2016) Cancer Statistics in China, 2015. CA: A Cancer Journal for Clinicians, 66, 115-132.  
&lt;br&gt;https://doi.org/10.3322/caac.21338</mixed-citation></ref><ref id="hanspub.43862-ref5"><label>5</label><mixed-citation publication-type="other" xlink:type="simple">吴一龙, 陆舜, 程颖, 等. 不可切除局部晚期/转移性非小细胞肺癌起始治疗共识[J]. 循证医学, 2020, 20(3): 129-134.</mixed-citation></ref><ref id="hanspub.43862-ref6"><label>6</label><mixed-citation publication-type="other" xlink:type="simple">黄仁军, 李勇刚. 能谱CT的临床应用与研究进展[J]. 放射学实践, 2015, 30(1): 81-83.</mixed-citation></ref><ref id="hanspub.43862-ref7"><label>7</label><mixed-citation publication-type="other" xlink:type="simple">李琦, 罗天友, 吕发金, 等. 能谱CT定量分析在确定非小细胞肺癌病理类型中的价值[J]. 中华放射学杂志, 2017, 51(4): 257-261.</mixed-citation></ref><ref id="hanspub.43862-ref8"><label>8</label><mixed-citation publication-type="other" xlink:type="simple">王朝军, 张蕾, 马霞, 等. 能谱CT在肺癌诊断及病理分型中的应用价值[J]. 中国CT和MRI杂志, 2018, 16(3): 33-36.</mixed-citation></ref><ref id="hanspub.43862-ref9"><label>9</label><mixed-citation publication-type="other" xlink:type="simple">Fehrenbach, U., Kahn, J., Ning, G., et al. (2019) Spectral CT and Its Specific Values in the Staging of Patients with Non-Small Cell Lung Cancer: Technical Possibilities and Clinical Impact. Clinical Radiology, 74, 456-466.  
&lt;br&gt;https://doi.org/10.1016/j.crad.2019.02.010</mixed-citation></ref><ref id="hanspub.43862-ref10"><label>10</label><mixed-citation publication-type="other" xlink:type="simple">陈良新, 朱玉娟. 能谱CT多参数分析在评估肺癌病理分型中的应用价值[J]. 中国CT和MRI杂志, 2019, 17(8): 68-71.</mixed-citation></ref><ref id="hanspub.43862-ref11"><label>11</label><mixed-citation publication-type="other" xlink:type="simple">胡蓉, 徐耀, 侯金鹏, 等. 能谱CT多参数定量分析对鉴别肺癌病理类型的价值[J]. 实用放射学杂志, 2019, 35(3): 464-468.</mixed-citation></ref><ref id="hanspub.43862-ref12"><label>12</label><mixed-citation publication-type="other" xlink:type="simple">黄倩文, 陈应东, 钟华, 等. 肺癌能谱CT相关参数定量与临床应用[J]. 临床放射学杂志, 2020, 39(7): 1316-1321.</mixed-citation></ref><ref id="hanspub.43862-ref13"><label>13</label><mixed-citation publication-type="other" xlink:type="simple">张仁锋, 张岩, 温丰标, 等. 6058例肺癌患者病理类型和临床流行病学特征的分析[J]. 中国肺癌杂志, 2016, 19(3): 129-135.</mixed-citation></ref><ref id="hanspub.43862-ref14"><label>14</label><mixed-citation publication-type="other" xlink:type="simple">韩立波, 李进东, 胡永校, 等. 肺癌淋巴结转移特点的研究[J]. 中华胸心血管外科杂志, 2003, 19(5): 275-277.</mixed-citation></ref><ref id="hanspub.43862-ref15"><label>15</label><mixed-citation publication-type="other" xlink:type="simple">刘江勇, 王荣品, 骆科进. 双源CT双能量虚拟平扫在肺癌诊断中的初步研究[J]. 临床放射学杂志, 2016, 35(9): 1367-1371.</mixed-citation></ref><ref id="hanspub.43862-ref16"><label>16</label><mixed-citation publication-type="other" xlink:type="simple">杨雯, 荣萍, 辛小燕, 等. 能谱CT虚拟平扫代替常规平扫应用于肺部占位性病变诊疗中的可行性[J]. 实用癌症杂志, 2021, 36(2): 280-282+286.</mixed-citation></ref></ref-list></back></article>